CNMD Relative Valuation
CNMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNMD is overvalued; if below, it's undervalued.
Historical Valuation
Conmed Corp (CNMD) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.16 is considered Undervalued compared with the five-year average of 28.74. The fair price of Conmed Corp (CNMD) is between 83.98 to 153.99 according to relative valuation methord. Compared to the current price of 52.40 USD , Conmed Corp is Undervalued By 37.61%.
Relative Value
Fair Zone
83.98-153.99
Current Price：52.40
37.61%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.72
P/B
Median3y
3.30
Median5y
3.89
9.79
FCF Yield
Median3y
4.03
Median5y
3.31
Competitors Valuation Multiple
The average P/S ratio for CNMD's competitors is 2.94, providing a benchmark for relative valuation. Conmed Corp Corp (CNMD) exhibits a P/S ratio of 1.22, which is -58.54% above the industry average. Given its robust revenue growth of 2.88%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Conmed Corp (CNMD) currently overvalued or undervalued?
What is Conmed Corp (CNMD) fair value?
How does CNMD's valuation metrics compare to the industry average?
What is the current P/B ratio for Conmed Corp (CNMD) as of Jul 08 2025?
What is the current FCF Yield for Conmed Corp (CNMD) as of Jul 08 2025?
What is the current Forward P/E ratio for Conmed Corp (CNMD) as of Jul 08 2025?